214 related articles for article (PubMed ID: 2901995)
1. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.
Eliakim R; Karmeli F; Razin E; Rachmilewitz D
Gastroenterology; 1988 Nov; 95(5):1167-72. PubMed ID: 2901995
[TBL] [Abstract][Full Text] [Related]
2. Cytokines and platelet-activating factor in human inflamed colonic mucosa.
Rachmilewitz D; Eliakim R; Simon P; Ligumsky M; Karmeli F
Agents Actions; 1992; Spec No():C32-6. PubMed ID: 1359744
[TBL] [Abstract][Full Text] [Related]
3. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.
Sharon P; Ligumsky M; Rachmilewitz D; Zor U
Gastroenterology; 1978 Oct; 75(4):638-40. PubMed ID: 30669
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor--a possible mediator in the pathogenesis of ulcerative colitis.
Rachmilewitz D; Karmeli F; Eliakim R
Scand J Gastroenterol Suppl; 1990; 172():19-21. PubMed ID: 1972295
[TBL] [Abstract][Full Text] [Related]
5. Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis.
Ferraris L; Karmeli F; Eliakim R; Klein J; Fiocchi C; Rachmilewitz D
Gut; 1993 May; 34(5):665-8. PubMed ID: 8504968
[TBL] [Abstract][Full Text] [Related]
6. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid.
Peskar BM; Dreyling KW; Peskar BA; May B; Goebell H
Agents Actions; 1986 Jun; 18(3-4):381-3. PubMed ID: 2875632
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey CJ; Lo Casto M
Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
[TBL] [Abstract][Full Text] [Related]
8. Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa.
Kolassa N; Becker R; Wiener H
Prostaglandins; 1985 Jan; 29(1):133-42. PubMed ID: 2858116
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
Rhodes JM; Bartholomew TC; Jewell DP
Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
[TBL] [Abstract][Full Text] [Related]
10. Modulation of human colonic arachidonic acid metabolism by sulfasalazine.
Hawkey CJ; Boughton-Smith NK; Whittle BJ
Dig Dis Sci; 1985 Dec; 30(12):1161-5. PubMed ID: 2866075
[TBL] [Abstract][Full Text] [Related]
11. Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.
Hillier K; Mason PJ; Pacheco S; Smith CL
Br J Pharmacol; 1982 May; 76(1):157-61. PubMed ID: 6123357
[TBL] [Abstract][Full Text] [Related]
12. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine.
Ligumsky M; Karmeli F; Sharon P; Zor U; Cohen F; Rachmilewitz D
Gastroenterology; 1981 Sep; 81(3):444-9. PubMed ID: 6114012
[TBL] [Abstract][Full Text] [Related]
13. Quantification of distinct molecular species of platelet activating factor in ulcerative colitis.
Thyssen E; Turk J; Bohrer A; Stenson WF
Lipids; 1996 Mar; 31 Suppl():S255-9. PubMed ID: 8729129
[TBL] [Abstract][Full Text] [Related]
14. PAF formation by human gastrointestinal mucosa/submucosa in-vitro: release by ricinoleic acid, and inhibition by 5-aminosalicylic acid.
Capasso F; Tavares IA; Bennett A
J Pharm Pharmacol; 1992 Sep; 44(9):771-2. PubMed ID: 1360533
[TBL] [Abstract][Full Text] [Related]
15. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.
Lauritsen K; Hansen J; Bytzer P; Bukhave K; Rask-Madsen J
Gut; 1984 Nov; 25(11):1271-8. PubMed ID: 6149981
[TBL] [Abstract][Full Text] [Related]
16. Potential role for interleukin-1 in the pathophysiology of ulcerative colitis.
Wardle TD; Turnberg LA
Clin Sci (Lond); 1994 May; 86(5):619-26. PubMed ID: 8033515
[TBL] [Abstract][Full Text] [Related]
17. Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon in vivo.
Goerg KJ; Wanitschke R; Gabbert H; Breiling J; Franke M; Meyer zum Büschenfelde KH
Digestion; 1987; 37(2):79-87. PubMed ID: 2887473
[TBL] [Abstract][Full Text] [Related]
18. Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid.
Capasso F; Tavares IA; Bennett A
Drugs Exp Clin Res; 1991; 17(7):351-3. PubMed ID: 1794301
[TBL] [Abstract][Full Text] [Related]
19. Platelet activating factor: release from colonic mucosa in patients with ulcerative colitis and its effect on colonic secretion.
Wardle TD; Hall L; Turnberg LA
Gut; 1996 Mar; 38(3):355-61. PubMed ID: 8675086
[TBL] [Abstract][Full Text] [Related]
20. Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation.
Nielsen ST; Beninati L; Buonato CB
Scand J Gastroenterol; 1988 Apr; 23(3):272-6. PubMed ID: 2898806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
